Replimune Group, Inc.

Aug 14, 2026

Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

Replimune Group, Inc. reported strong financial results for Q1 2027, highlighted by the FDA's accelerated approval of TUDRIQEV for advanced melanoma. The company is preparing for a commercial launch within 60 days and has secured $150 million in financing to support this effort. Additionally, Michelle DiNapoli has been appointed as Chief Commercial Officer to enhance the company's commercial strategy.

Aug 10, 2026

▲ +13.3%on this news· ran to +26% by day 3

Replimune Announces Pricing of $150 Million Underwritten Offering

Replimune Group, Inc. has announced the pricing of an underwritten offering of 9,701,490 shares of its common stock, raising $150 million. This move is expected to enhance the company's financial resources, enabling further development of its innovative oncolytic immunotherapies. The offering reflects investor confidence in Replimune's growth potential.

Aug 6, 2026

▼ -6.2%on this news· ran to +19% by day 3shared move

Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen

Replimune Group, Inc. announced the FDA's accelerated approval of TUDRIQEV in combination with nivolumab for adults with unresectable advanced cutaneous melanoma who have progressed on anti-PD-1 therapy. The approval is based on a 24.2% objective response rate observed in the IGNYTE trial. The treatment was well tolerated, although continued approval may depend on further clinical trials to verify its benefits.

Jul 30, 2026

▲ +107%on this news· ran to +120% by day 1

Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma

Replimune Group, Inc. announced a favorable outcome from the FDA's advisory committee meeting regarding the BLA resubmission for RP1 in advanced melanoma. The committee voted 10 to 3 on the clinical meaningfulness of the efficacy results from the IGNYTE study. The FDA's target action date for the BLA is August 2, 2026.

Jun 29, 2026

Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update

Replimune Group reported its fiscal fourth quarter and year-end results, highlighting the FDA's acceptance of the BLA resubmission for RP1 in advanced melanoma. The company is actively enrolling patients in its clinical trials for RP1 and RP2, with promising survival data presented at ASCO 2026. However, the company reported a significant net loss and a decrease in cash reserves compared to the previous year.

Jun 26, 2026

Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma

Replimune Group, Inc. announced that the FDA has accepted its resubmission of the Biologics License Application for RP1 in combination with nivolumab for advanced melanoma. The FDA's action is classified as a complete, class 1 response, with an advisory committee meeting expected in late July. The resubmission aims for accelerated approval based on the IGNYTE clinical trial data.

May 31, 2026

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

Replimune Group presented final first-in-human data for RP2 at the 2026 ASCO meeting. The Phase 1 trial involved 85 patients with advanced solid tumors, showing an objective response rate of 19.0% for RP2 monotherapy and 19.1% when combined with nivolumab. The results indicate durable responses and a favorable safety profile, supporting further evaluation in a Phase 2/3 trial.

May 30, 2026

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

Replimune Group, Inc. presented promising 3-year overall survival data from the IGNYTE clinical trial at the 2026 ASCO annual meeting. The trial evaluated RP1 plus nivolumab in patients with anti-PD-1 failed melanoma, showing a median overall survival of 32.9 months. Notably, 47.8% of all treated patients survived at three years, with 83.5% survival among responders, highlighting the treatment's durability and effectiveness.

May 29, 2026

▲ +85.7%on this news· ran to +113% by day 3shared move

Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA

Replimune Group, Inc. has announced plans to resubmit its Biologics License Application (BLA) for RP1 following productive discussions with the FDA. The agency has committed to treating the resubmission as urgent, recognizing the unmet needs in advanced melanoma treatment. The BLA is supported by clinical trial data, highlighting the need for new therapies as current options often fail.

Apr 27, 2026

▲ +10.7%on this news

Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Replimune Group, Inc. announced its participation in the 2026 ASCO Annual Meeting, where it will present multiple abstracts. Key presentations include a landmark survival analysis from the IGNYTE trial and final results from a Phase 1 study of RP2. The event will showcase advancements in oncolytic immunotherapies for melanoma and other solid tumors.

Replimune Group, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Replimune Group, Inc. is under investigation by Johnson Fistel for possible recovery of losses suffered by investors after the FDA issued a Complete Response Letter. This letter highlighted deficiencies in the data supporting the company's Biologics License Application for RP1, stating that the evidence presented was insufficient. Despite prior attempts to address these issues, the company's stock price has markedly declined, prompting concerns regarding compliance with federal securities laws. Shareholders who suffered losses are encouraged to participate in the investigation.

Apr 10, 2026

▼ -19.5%on this news· ran to -71% by day 1shared move

Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma

Replimune Group received a complete response letter from the FDA for its RP1 biologics license application for advanced melanoma. The company disagrees with the FDA's assessment of the data supporting RP1's efficacy and safety. This decision has led to job cuts and a scaling back of operations, as the company struggles with the regulatory process. The situation highlights concerns over FDA communication and innovation in cancer treatment.

Mar 2, 2026

▼ -6.4%on this news

Replimune to Present at Two Upcoming Investor Conferences

Replimune Group, Inc. announced that its management team will present at two upcoming investor conferences: the Leerink Partners 2026 Global Healthcare Conference and the Jefferies 2026 Biotech on the Beach Summit. The presentations will include a fireside chat and 1x1 meetings. Live webcasts will be available on their website.

Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

Replimune Group, Inc. reported its fiscal third quarter 2026 financial results, highlighting the acceptance of its BLA resubmission for RP1 by the FDA. The company is preparing for a potential launch, pending FDA approval, with commercial readiness activities in progress. Additionally, Replimune amended its loan agreement to extend its cash runway into early 2027.

Jan 14, 2026

Replimune Group Inc. JPM 2026 Presentation Click to edit Master title style 1 Click to edit Master text styles Igniting a systemic immune response to cancer with oncolytic immunotherapy

Replimune Group Inc. presented at the 2026 JPM Healthcare Conference, highlighting the progress of their RPx oncolytic immunotherapy. The company is set to pursue a PDUFA date of April 10, 2026, for melanoma treatment, leveraging a launch-ready commercial team. The presentation detailed clinical trial advancements and the platform's ability to deliver significant immune responses, particularly in resilient cancer cases. However, the company acknowledged various risks that could affect projected outcomes as they navigate the complexities of development and regulatory approval.

Dec 18, 2025

Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference

Replimune Group, Inc., a clinical stage biotechnology company based in Woburn, MA, has announced that its management will present at the 44th Annual J.P. Morgan Healthcare Conference scheduled for January 14, 2026. The company focuses on developing novel oncolytic immunotherapies using its proprietary RPx platform. This platform aims to enhance immunogenic cell death and systemic anti-tumor immune responses, offering potential synergy with existing cancer treatments. A webinar of the presentation will be available on their website for interested investors and stakeholders.

Nov 7, 2025

Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)

Replimune Group, Inc. presented late-breaking abstract data from the IGNYTE trial at the SITC 2025, highlighting the potential of RP1 combined with nivolumab in treating melanoma. The data suggest that this combination may help overcome resistance to immune checkpoint blockade. Additionally, two posters on RP1 were also showcased at the conference.

Nov 6, 2025

Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update

Replimune Group, Inc. reported its fiscal second quarter 2026 financial results and announced that the FDA accepted the BLA resubmission for RP1 to treat advanced melanoma. The PDUFA target action date is set for April 10, 2026. The acceptance follows a complete response to a previous letter from the FDA, indicating potential support from the IGNYTE-3 trial for approval.

Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma

Replimune Group, Inc. announced that the FDA has accepted the resubmission of its Biologics License Application for RP1, intended for treating advanced melanoma. The combination of RP1 with nivolumab is aimed at patients who have progressed on anti-PD-1 therapy. The FDA set a PDUFA date of April 10, 2026, for this application.

Oct 19, 2025

▲ +98.8%on this newsshared move

Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025

Replimune Group presented promising data on RP1 combined with nivolumab for treating acral melanoma at the ESMO Congress 2025. The analysis revealed a 44% objective response rate and a median duration of response of 11.9 months. The treatment exhibited a favorable safety profile, primarily involving transient adverse events. The ongoing IGNYTE-3 trial is evaluating this combination further.

Oct 8, 2025

REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Replimune Group, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. is investigating Replimune Group, Inc. following a class action complaint filed against the company. The lawsuit, which pertains to the period between November 22, 2024, and July 21, 2025, alleges that Replimune made misleading statements about the prospects of its IGNYTE trial. This resulted in the FDA deeming the trial inadequate. The law firm is urging affected long-term stockholders to discuss their legal options.

Sep 22, 2025

REPLIMUNE FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urges Replimune Group, Inc. Investors to Contact the Firm Regarding Class Action Lawsuit

Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Replimune Group, Inc. for false and misleading statements made during the company's Class Period from November 22, 2024 to July 21, 2025. Allegations include the overstatement of the IGNYTE trial's prospects, which led the FDA to deem it inadequate. Investors who suffered losses must apply to the court by September 22, 2025, if they wish to be considered as lead plaintiffs.

Sep 19, 2025

▼ -6.8%on this news· ran to +20% by day 3shared move

REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Replimune Group, Inc. and Encourages Investors to Contact the Firm Before September 22nd

Bragar Eagel & Squire, P.C. has announced that a class action lawsuit has been filed against Replimune Group, Inc. in the U.S. District Court for the District of Massachusetts. The lawsuit involves allegations that the company made materially false and misleading statements regarding the prospects of the IGNYTE trial. It is suggested that these misleading statements resulted in financial harm to investors when the true details about the trial's inadequacies were revealed. Affected investors have until September 22, 2025, to apply for lead plaintiff status in the lawsuit.

Sep 18, 2025

▼ -39.4%on this newsshared move

Replimune Provides Update Following Type A Meeting with FDA

Replimune Group, Inc. announced the completion of a Type A meeting with the FDA to discuss the complete response letter for its Biologics License Application for RP1 in advanced melanoma treatment. The company is evaluating FDA feedback to determine next steps, but an accelerated approval pathway has not yet been established. CEO Sushil Patel emphasized the importance of RP1 in addressing unmet needs in melanoma care.

Sep 18, 2025

▼ -39.4%on this newsshared move

Replimune Group, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 22, 2025 Deadline to file Lead Plaintiff Motion.

The Portnoy Law Firm is advising Replimune Group investors to join a class action lawsuit after significant losses due to misleading statements about their clinical trial. The lawsuit relates to events between November 2024 and July 2025 and alleges the company overstated the potential success of its IGNYTE trial. Following a Complete Response Letter from the FDA stating the trial was not well-controlled, Replimune's stock plummeted over 77%. Investors have until September 22, 2025, to file a lead plaintiff motion.

Sep 18, 2025

▼ -39.4%on this newsshared move

REPLIMUNE GROUP, INC. (NASDAQ: REPL) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Replimune Group, Inc. Investors of Upcoming Deadline

Replimune Group, Inc. is involved in a securities fraud class action lawsuit initiated by Bernstein Liebhard LLP. The lawsuit affects investors who purchased shares between November 22, 2024, and July 21, 2025, and accuses the company of making false statements about the prospects of its drug RP1 in the IGNYTE trial. Investors may opt to join the lawsuit or remain absent class members, with the deadline for serving as lead plaintiff set for September 22, 2025. Bernstein Liebhard LLP represents the plaintiffs on a contingency fee basis.

Sep 10, 2025

Replimune Group, Inc. Class Action: The Gross Law Firm Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025 – REPL

Replimune Group, Inc. is currently facing a class action lawsuit initiated by The Gross Law Firm. The lawsuit alleges that during the class period from November 22, 2024, to July 21, 2025, the company misrepresented the prospects of the IGNYTE trial. As a result, the FDA has classified the trial as inadequate. Shareholders are encouraged to register for the lawsuit by September 22, 2025, to potentially serve as lead plaintiffs.

Sep 10, 2025

Replimune (REPL) Faces Investor Lawsuit After FDA Blocks Cancer Drug Approval - Hagens Berman

Replimune Group Inc. is facing a securities class action lawsuit from investors following the FDA's rejection of its cancer therapy RP1. The lawsuit claims the company misrepresented the likelihood of regulatory success and concealed risks regarding the trial's design. The FDA halted the approval process after finding deficiencies in the clinical trial data, which has led to a dramatic 77% drop in the company's stock price. The firm is currently under investigation for potential misleading disclosures related to the trial's results and their implications for investors.

Sep 7, 2025

REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Replimune Group, Inc. and Encourages Investors to Contact the Firm

A class action lawsuit has been initiated against Replimune Group, Inc. for allegedly making false statements regarding the IGNYTE trial. The law firm Bragar Eagel & Squire, P.C. announced the lawsuit on behalf of investors who acquired Replimune securities from November 22, 2024, to July 21, 2025. The lawsuit claims that the company overstated the trial's prospects, leading to significant investor losses. Interested investors have until September 22, 2025, to apply to be appointed as lead plaintiffs in this case.

Sep 3, 2025

REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Replimune Group, Inc. on Behalf of Replimune Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. is investigating Replimune Group, Inc. on behalf of its stockholders regarding possible violations of federal securities laws. The investigation centers on allegations that Replimune misled investors about the prospects of its IGNYTE trial, leading to a Complete Response Letter (CRL) from the FDA. The CRL indicated that the trial was inadequate and not well-controlled, which significantly impacted Replimune's stock price, causing it to drop by over 77%. Investors who have suffered losses are encouraged to contact the law firm to discuss their legal options.

Sep 2, 2025

▲ +9.3%on this newsshared move

Replimune Announces Type A Meeting Scheduled with FDA

Replimune Group, Inc. has announced a Type A meeting with the FDA to discuss the complete response letter regarding its Biologics License Application for RP1 in advanced melanoma. The company submitted a briefing book addressing FDA concerns and is eager to resolve issues for accelerated approval. The urgency is emphasized by support from the melanoma community for RP1's access.

Sep 2, 2025

▲ +9.3%on this newsshared move

Replimune (REPL) Faces Investor Lawsuit Following 77% Stock Crash After FDA Rejects Key Drug - Hagens Berman

Replimune Group, Inc. is facing a securities class action lawsuit after a significant drop in stock value due to the FDA's rejection of its cancer drug, RP1. The Complete Response Letter indicated design and methodological flaws in the underlying clinical trial, leading to a 77% plummet in stock price. The lawsuit alleges that the company misrepresented trial data and downplayed regulatory risks to investors. Legal firm Hagens Berman is investigating these claims on behalf of those who suffered losses during the relevant trading period.

Aug 22, 2025

Replimune (REPL) Faces Securities Class Action Following Stock’s Collapse Amid FDA’s Rejection of Melanoma Drug - Hagens Berman

Replimune Group, Inc. faces a securities class action lawsuit after a significant 77% drop in its stock price, triggered by the FDA's rejection of its melanoma drug RP1. The FDA issued a Complete Response Letter citing serious inadequacies in the IGNYTE trial, alleging that the company did not provide adequate evidence of the drug's effectiveness. The lawsuit claims that Replimune misrepresented the clinical data supporting RP1 and failed to disclose significant flaws in the trial design. Investors who acquired Replimune securities in the affected period are encouraged to join the lawsuit as they seek to recover losses.

Aug 20, 2025

Replimune (REPL) Faces Securities Class Action Following Stock’s Collapse Amid FDA’s Rejection of Melanoma Drug – Hagens Berman

Replimune Group, Inc. is facing a securities class action following a 77% collapse in its stock price after the FDA issued a Complete Response Letter for their melanoma drug, RP1. The lawsuit alleges misrepresentation regarding the strength of clinical data supporting the drug's approval. Specifically, it claims that Replimune overstated the likelihood of success for its IGNYTE trial while failing to disclose significant design and data inadequacies that ultimately led to the FDA's rejection. Hagens Berman is investigating potential violations of U.S. securities laws linked to these claims.

Aug 7, 2025

Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update Woburn, MA

Replimune Group, Inc. reported its fiscal first quarter 2026 financial results, detailing a net loss of $86.7 million. The announcement included a business update indicating that the FDA issued a Complete Response Letter for its lead product candidate RP1 in advanced melanoma. Despite the challenges, the CEO emphasized the strong belief within the melanoma community that RP1 should be made available to patients soon. The company anticipates its current financial resources will support operations into the fourth quarter of 2026, allowing for potential commercialization efforts.

Aug 7, 2025

Replimune Group, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before September 22, 2025 to Discuss Your Rights – REPL

Replimune Group, Inc. is under scrutiny as The Gross Law Firm has announced a lawsuit against the company for securities law violations. The class period in question spans from November 22, 2024, to July 21, 2025, during which the company allegedly made false and misleading statements regarding the IGNYTE trial's success. The FDA has deemed the trial inadequate, further complicating the company's credibility. Shareholders affected by these allegations are encouraged to contact the law firm for potential lead plaintiff appointment and recovery options.

Aug 5, 2025

▲ +10.7%on this newsshared move

Replimune Group, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights – REPL

Replimune Group, Inc. is currently facing a class action securities lawsuit initiated by Levi & Korsinsky, LLP. The lawsuit, which covers actions between November 22, 2024 and July 21, 2025, alleges that the company made false statements about its IGNYTE trial. Specifically, the complaint asserts that Replimune officials overstated the trial's potential, despite knowing of significant issues that led to the FDA's finding that the trial was inadequate. Investors affected by the alleged fraud are encouraged to contact the law firm to discuss their rights.

Jul 25, 2025

Replimune Group, Inc. Investors: Company Investigated by the Portnoy Law Firm

Replimune Group, Inc. is under investigation by the Portnoy Law Firm for potential securities fraud following a disappointing FDA response. The FDA issued a Complete Response Letter regarding Replimune's Biologics License Application for RP1, citing inadequate evidence of effectiveness from the IGNYTE trial. As a result of the negative announcement, the company's stock plummeted more than 77%, raising concerns among investors. The law firm is reaching out to affected investors to explore legal options for recovering losses.

Jul 23, 2025

▲ +18.9%on this newsshared move

Replimune (REPL) Shares Plummet After FDA Rejects Melanoma Drug, Sparking Investor Concerns - Hagens Berman

Replimune Group's stock plummeted by 77% after the FDA rejected its melanoma drug application for RP1. This decision was based on issues with the design and execution of the IGNYTE trial, which the FDA determined lacked solid proof of the drug's effectiveness. As a result, there is now an investigation by the law firm Hagens Berman into the company's statements regarding the trial data. The situation has raised concerns among investors about the integrity of Replimune's communications.

Jul 22, 2025

▼ -77.2%on this newsshared move

Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma

Replimune Group announced that the FDA has issued a Complete Response Letter for its RP1 Biologics License Application for advanced melanoma treatment. The FDA cited inadequacies in the IGNYTE trial, stating it did not provide substantial evidence of effectiveness. Replimune plans to request a Type A meeting to discuss the issues raised and seek a path forward for the approval of RP1.

Jul 11, 2025

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Replimune Group, Inc. has granted inducement equity awards to 16 newly hired non-executive employees as part of its 2025 Inducement Grant Incentive Compensation Plan. The awards include non-qualified stock options and restricted stock units, with specific vesting schedules. This move is intended to attract talent and is compliant with Nasdaq Listing Rule 5635(c)(4).

May 22, 2025

Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update BLA priority review of RP1 plus nivolumab in advanced melanoma proceeding on schedule; manufacturing inspections a

Replimune Group, Inc. has reported its fiscal fourth quarter and year-end financial results for 2025, highlighting the progression of its BLA priority review of RP1 in combination with nivolumab for advanced melanoma. The company confirms that it is prepared for the commercial launch scheduled for July 2022 with a fully staffed organization and a planned optimized delivery approach. Financially, Replimune is positioned to operate into Q4 2026 but reported a significant net loss for the fiscal year, raising concerns about financial sustainability amidst ongoing expenditures.

Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in adva

Replimune Group, Inc. announced its fiscal third quarter 2025 financial results and a corporate update. The FDA has accepted the Biologics License Application for RP1 in advanced melanoma, with a priority review and a PDUFA date set for July 22, 2025. The company also reported a significant net loss and increasing operating expenses but remains well-capitalized with over $500 million in cash. Ongoing clinical trials for RP2 and ongoing patient enrollments highlight Replimune's commitment to advancing its innovative therapies.

Jan 21, 2025

▲ +16.9%on this news· ran to +34% by day 3

Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma

Replimune Group, Inc. announced that the FDA has accepted its Biologics License Application for RP1 in combination with nivolumab to treat advanced melanoma. This application has been granted Priority Review status, with a required action date set for July 22, 2025. The BLA's support stems from promising data in the IGNYTE clinical trial, which involved patients who failed anti-PD-1 treatments. Alongside this application, a Phase 3 trial, IGNYTE-3, is currently in progress at over 100 global sites to confirm the efficacy of RP1.

Replimune Announces Proposed Public Offering

Replimune Group, Inc. has announced a proposed public offering of $125 million of its common stock and pre-funded warrants, with the option for underwriters to purchase an additional $18.75 million. This offering is contingent upon market conditions and is subject to regulatory approval, with full details to be disclosed in a prospectus to be filed with the SEC. Founded in 2015, Replimune is focused on developing novel oncolytic immunotherapies, leveraging its proprietary RPx platform for cancer treatment.

Nov 21, 2024

Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway

Replimune Group, Inc. has announced the submission of its biologics license application (BLA) for RP1 in combination with nivolumab to the FDA under the Accelerated Approval pathway. The FDA has also granted Breakthrough Therapy designation for this treatment, aimed at adult patients with advanced melanoma who have already undergone anti-PD1 therapy. This designation is expected to expedite development due to promising preliminary clinical evidence. The Phase 3 IGNYTE-3 trial is currently enrolling patients to further investigate the efficacy of RP1.

Nov 12, 2024

Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update Completed Pre-Biologics License Application (BLA) meeting with the U.S. Food and Drug Administration (FDA) and remain on track

Replimune Group, Inc. announced its fiscal second quarter 2025 financial results and provided a corporate update, highlighting significant progress towards the BLA submission for its lead product, RP1. The company reported a strong financial position, with enough cash reserves to sustain operations through the second half of 2026. Positive reactions to recent clinical data from the oncology community were noted, reflecting the potential impact of their oncolytic immunotherapy approach. However, the company also reported an increase in net losses compared to the previous year, raising questions about its long-term financial wellness.

Aug 8, 2024

Replimune Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update Pre-Biologics License Application (BLA) meeting with the U.S. Food and Drug Administration (FDA) scheduled for September and BLA

Replimune Group, Inc. reported its financial results for the fiscal first quarter of 2025 and provided an update on its corporate activities. The company is poised for a pre-BLA meeting with the FDA regarding its RP1 product candidate, which aims to treat anti-PD1 failed melanoma patients. Financially, Replimune projects that its existing cash will support operations through the second half of 2026, alongside advancements in its clinical pipeline, including the RP2 program targeting uveal melanoma.

Replimune Announces $100 Million Private Placement Financing - Led by a life-sciences focused institutional investor, with participation from Redmile Group, RTW Investments, Boxer Capital and other institutional investor

Replimune has announced a successful $100 million private placement financing, led by a life-sciences institutional investor, with participation from prominent groups such as Redmile and RTW Investments. The funds will be utilized to fully scale up for the commercialization of their RP1 therapy in skin cancers, aiming for a potential market launch in the second half of 2025. The financing follows encouraging primary analysis results from the RP1 IGNYTE clinical trial, supporting the company's upcoming BLA filing expected in the latter half of 2024.

Jun 6, 2024

▲ +27.9%on this news· ran to +62% by day 3

Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma Primary endpoint data shows 12-month overall response

Replimune Group, Inc. announced positive topline results from the primary analysis of its IGNYTE clinical trial for RP1 plus nivolumab in patients with anti-PD1 failed melanoma. The independent review reported a 12-month overall response rate of 33.6%, and all responses lasted over six months, indicating promising durability. The company plans to proceed with a BLA submission in the second half of 2024 and expects patient enrollment in a confirmatory trial soon.

Jun 3, 2024

Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting -- Investigator-assessed 12-month results from the IGNYTE clinical trial of RP1

Replimune Group presented encouraging data from its RP1 and RP2 clinical programs at the 2024 ASCO Annual Meeting. The IGNYTE trial for RP1 in anti-PD-1 failed melanoma showed a 12-month overall response rate of 32.7%, reaffirming previous findings. RP2, both as a monotherapy and in combination with nivolumab, demonstrated a response rate of nearly 30% in uveal melanoma, highlighting its potential in treatment-resistant cases. The company is on track to submit a biologics license application (BLA) for RP1 in the second half of 2024.

May 16, 2024

Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update Twelve-month primary analysis results by independent central review from the IGNYTE clinical trial of RP1 (vusol

Replimune Group, Inc. announced its fiscal fourth quarter and year-end 2024 financial results, highlighting significant corporate updates. The company is poised to share primary analysis results from its IGNYTE clinical trial and plans to initiate patient enrollment for its Phase 3 IGNYTE-3 trial in the second half of the year. With secured funding expected to last into late 2026, Replimune aims to bring its first oncolytic immunotherapy to market, pending FDA approval. However, the reported net loss and increased operating expenses raise concerns regarding financial stability.

Mar 26, 2024

Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions Philip Astley-Sparke to transition from current role of CEO to Executive Chairman Planned leadership changes position the compan

Replimune Group, Inc. has announced the appointment of Sushil Patel as the new CEO, succeeding Philip Astley-Sparke, who will become Executive Chairman. This leadership change aims to support the company's preparations for the upcoming commercialization of RP1, with a biologics license application scheduled for submission in the second half of 2024. Patel brings over 20 years of experience in the biotech sector, having previously served as the Chief Commercial Officer and Chief Strategy Officer at Replimune. The company remains focused on its strategic priorities, including data submission and confirmatory studies for RP1.

Feb 8, 2024

Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update Positive data update in December 2023 for all 140 patients in the IGNYTE clinical trial cohort of RP1 in anti-PD1 failed melanom

Replimune Group, Inc. reported its fiscal third quarter 2024 financial results and shared an update on its corporate strategy. The company highlighted promising data for its RP1 treatment in skin cancers, planning to submit a Biologics License Application (BLA) for anti-PD1 failed melanoma in the second half of 2024. Additionally, they announced an extended cash runway projected to last until the second half of 2026. However, the company also noted an increase in operational losses year-over-year, underscoring the financial challenges it faces in achieving its clinical goals.

Safe harbor Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Sect

Replimune Group Inc. announced positive updates on its anti-cancer treatment pipeline, particularly highlighting the success of RP1 in treating uveal melanoma. The company reported durable responses in a recent trial, with some patients experiencing a partial response for over 24 months. Replimune also revealed its solid financial position, with significant cash reserves projected to support operations through 2026. A BLA submission for RP1 is planned for the second half of 2024, aiming to address significant unmet needs in the oncology space.

Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Mela

Replimune Group, Inc. has released initial primary analysis results from the CERPASS clinical trial, which evaluated RP1 in combination with cemiplimab for advanced cutaneous squamous cell carcinoma. Although the study demonstrated a clinically meaningful improvement in complete response rates, it did not meet its two primary endpoints. Concurrently, data from the IGNYTE clinical trial suggests durable benefits of RP1 in patients with anti-PD1 failed melanoma, with a biologics license application planned for submission in the second half of 2024. Challenges remain, including baseline tumor burden imbalances that could impact outcomes.

Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update The Company plans to hold a conference call in early December to provide a comprehensive RP1 skin cancer program update includi

Replimune Group, Inc. has reported its fiscal second quarter 2024 financial results, highlighting ongoing developments in their clinical trials for RP1, a novel oncolytic immunotherapy. The company plans to share topline data from significant clinical trials in an upcoming investor call, alongside updates related to regulatory pathways for potential drug approval. Despite facing considerable operating losses, Replimune's financial status is projected to sustain operations into the latter part of 2025. The firm is also working on confirmatory studies to support applications for regulatory approval.

Sep 19, 2023

Replimune Announces Appointment of Emily Hill as Chief Financial Officer Woburn, MA

Replimune Group, Inc. has appointed Emily Hill as Chief Financial Officer. With over 15 years of experience in the biotechnology industry, Ms. Hill previously served as CFO at PTC Therapeutics, where she contributed to the company's substantial growth. Her expertise in financial planning will play a crucial role as Replimune transitions from a clinical stage to a commercial stage company. The company anticipates upcoming data from two potentially registrational trials, marking significant value inflection points.

Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update Topline data from the registration-directed CERPASS clinical trial of RP1 combined with Libtayo (cemiplimab-rwlc) in cutaneous s

Replimune Group, Inc. announced its financial results for the first fiscal quarter of 2024 and provided updates on its clinical trials. The company reported positive developments for its lead candidate RP1, particularly in anti-PD1 failed melanoma, with upcoming data from key trials expected in late 2023 and early 2024. A cost-sharing collaboration with Incyte has been established for the neoadjuvant treatment of cutaneous squamous cell carcinoma. Replimune's cash reserves are projected to sustain operations until the second half of 2025.

Replimune Announces Sander Slootweg will Depart from its Board of Directors

Replimune Group, Inc. has announced that Sander Slootweg will not be reappointed as a non-executive director at the upcoming annual general meeting. Slootweg, the founder and managing partner at Forbion, expressed pride in the company's achievements since its inception. The CEO praised Slootweg's contributions, highlighting the value of his advice and Forbion's support for Replimune's mission in cancer treatment. Replimune continues to develop its proprietary tumor-directed immunotherapy platform aimed at enhancing patient outcomes in cancer care.

Replimune Appoints Veleka R. Peeples-Dyer to its Board of Directors Woburn, MA

Replimune Group, Inc. has appointed Veleka R. Peeples-Dyer to its Board of Directors, effective immediately. With over 24 years of experience in the life sciences sector, Peeples-Dyer brings significant expertise in legal and compliance matters to the board. She has held executive roles in leading biopharmaceutical companies and was recognized as a leader in the industry. The appointment aims to enhance Replimune's board as the company advances its pipeline of oncolytic immunotherapies.

May 18, 2023

Replimune Reports Fiscal Fourth Quarter and Year Ended 2023 Financial Results and Provides Corporate Update Topline data disclosure from the registration-directed CERPASS clinical trial of RP1 combined with Libtayo (cemi

Replimune Group, Inc. announced its fiscal fourth quarter and year-end financial results, highlighting significant upcoming milestones in their clinical development pipeline. The company expects to release topline data from the CERPASS clinical trial of RP1 in combination with Libtayo for cutaneous squamous cell carcinoma in Q3 2023 and plans to submit a Biologics License Application by Q1 2024. Additionally, they have completed enrollment in the IGNYTE trial and anticipate presenting updated data at ASCO. With a strong cash runway, the company is set to initiate new Phase 2 programs in various cancer types in the near future.

Replimune Reports Fiscal Third Quarter Financial Results and Provides Corporate Update Strengthened balance sheet raising gross $259 million through an upsized public offering in December, extending cash runway into H2 2

Replimune Group, Inc. reported fiscal third-quarter financial results for the period ended December 31, 2022, highlighting a strengthened balance sheet after raising $259 million through a public offering. The company aims to extend its cash runway into the second half of 2025, allowing for continued clinical advancements in cancer therapies. Positive data from the IGNYTE trial for RP1 in melanoma and planned updates from the CERPASS trial in cutaneous squamous cell carcinoma are expected in Q3 2023. Collaborative efforts with Roche for colorectal and liver cancer studies further enhance Replimune's strategic positioning.

Jan 4, 2023

Replimune Appoints Former Sanofi U.S. Commercial Oncology Head, Chris Sarchi, as Chief Commercial Officer and Sushil Patel as Chief Strategy Officer Woburn, MA

Replimune Group, Inc. has announced key leadership appointments, naming Christopher Sarchi as Chief Commercial Officer and Sushil Patel as Chief Strategy Officer. Sarchi's extensive experience in oncology, particularly with successful launches of cancer therapies, positions him to effectively lead the company's commercial strategy ahead of the anticipated launch of RP1 in 2024. Patel, previously the Chief Commercial Officer, will focus on strategizing the U.S. market entry for RP1 and explore international commercialization opportunities.

Dec 7, 2022

▲ +22.2%on this news· ran to +38% by day 3

Replimune Announces Proposed Public Offering Boston, MA

Replimune Announces Proposed Public Offering December 7, 2022 - Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced a proposed public offering of $1

Dec 7, 2022

▲ +22.2%on this news· ran to +38% by day 3

Replimune Enters into Clinical Collaboration Agreement with Roche for the Development of RP3 In Colorectal Cancer and Hepatocellular Carcinoma RP3 will be developed in combination with atezolizumab and bevacizumab for th

into Clinical Collaboration Agreement with Roche for the Development of RP3 In Colorectal Cancer and Hepatocellular Carcinoma RP3 will be developed in combination with atezolizumab and bevacizumab for the third-line treatment of colorectal cancer (CRC) and for the first- and se

Nov 3, 2022

Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update Completed enrollment in the CERPASS registration-directed clinical trial evaluating RP1 in cutaneous squamous cell carcinoma (CSCC);

Fiscal Second Quarter Financial Results and Provides Corporate Update Completed enrollment in the CERPASS registration-directed clinical trial evaluating RP1 in cutaneous squamous cell carcinoma (CSCC); primary analysis data expected to be released in H1 2023 Six-month follow-

Oct 7, 2022

Replimune Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc. Woburn, MA

$200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc. Woburn, MA, October 7, 2022 - Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today ann

Aug 4, 2022

Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update Target enrollment of 180 patients reached in the CERPASS randomized controlled registration-directed clinical trial evaluating RP1 in

Fiscal First Quarter Financial Results and Provides Corporate Update of 180 patients reached in the CERPASS randomized controlled registration-directed clinical trial evaluating RP1 in cutaneous squamous cell carcinoma (CSCC); primary analysis data expected to be released in H1

Replimune Announces the Departure of Jason Rhodes from its Board of Directors Woburn, MA

Announces the Departure of Jason Rhodes from its Board of Directors Woburn, MA, June 3, 2022 - Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced

May 19, 2022

Replimune Reports Fiscal Fourth Quarter and Year-Ended 2022 Financial Results and Provides Corporate Update Enrollment in the CERPASS clinical trial with RP1 in cutaneous squamous cell carcinoma (CSCC) expected to be com

Replimune Reports Fiscal Fourth Quarter and Year-Ended 2022 Financial Results and Provides Corporate Update Enrollment in the CERPASS clinical trial with RP1 in cutaneous squamous cell carcinoma (CSCC) expected to be completed in mid-year 2022; top line data expected Q1 2023

Mar 30, 2022

Replimune Provides New Clinical Data, Broad Program Update and Future Development Strategy for its Tumor-Directed Oncolytic Immunotherapies RP1 combined with Opdivo (nivolumab) continues to demonstrate deep and durable r

New Clinical Data, Broad Program Update and Future Development Strategy for its Tumor-Directed Oncolytic Immunotherapies with Opdivo (nivolumab) continues to demonstrate deep and durable responses in patients with melanoma and non-melanoma skin cancers (NMSC); new positive init

Feb 3, 2022

Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update Data expected to be presented at an investor event in March 2022: Data updates from the completed RP1 IGNYTE cohorts in anti-PD1 na v

Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update Data expected to be presented at an investor event in March 2022: Data updates from the completed RP1 IGNYTE cohorts in anti-PD1 na ve non-melanoma skin cancer (NMSC) and anti-PD1 na ve an

Jan 31, 2022

▲ +6.6%on this newsshared move

Replimune Announces the Departure of Dr. Otello Stampacchia from its Board of Directors Woburn, MA

Announces the Departure of Dr. Otello Stampacchia from its Board of Directors Woburn, MA, January 31, 2022 - Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, to

Jan 10, 2022

Replimune Provides 2021 Year End Review and Overview of Expected 2022 Milestones CERPASS clinical trial with RP1 in CSCC on track to complete enrollment mid-year with the primary analysis trigger six months thereafter IG

Provides 2021 Year End Review and Overview of Expected 2022 Milestones CERPASS clinical trial with RP1 in CSCC on track to complete enrollment mid-year with the primary analysis trigger six months thereafter anti-PD1 failed melanoma, evaluating RP1 in combination with Opdivo

Dec 2, 2021

Replimune Appoints Christy Oliger to its Board of Directors Woburn, MA

Appoints Christy Oliger to its Board of Directors Woburn, MA, December 2, 2021 - Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing a range of product candidates derived from its oncolytic immuno-gene therapy platform, today announced the appointment of C

Nov 4, 2021

Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update RP1; Full patient accrual in CERPASS registration-directed clinical trial continues to be expected in mid-year 2022 with the primary

Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update RP1; Full patient accrual in CERPASS registration-directed clinical trial continues to be expected in mid-year 2022 with the primary data trigger expected in late 2022. Interim data in the

Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update Updated complete and durable response data in RP1 (vusolimogene oderparepvec) skin cancer cohorts support the ongoing registration di

Fiscal First Quarter Financial Results and Provides Corporate Update Updated complete and durable response data in RP1 (vusolimogene oderparepvec) skin cancer cohorts support the ongoing registration directed development programs in CSCC and anti-PD-1 failed melanoma, with ful

Jun 3, 2021

Replimune Provides Data Update from its RP1 (vusolimogene oderparepvec) and RP2 Programs and Announces Plans to Expand the Development of RP2/3 Beyond Phase 1 High rate of complete responses in RP1 skin cancer cohorts un

Replimune Provides Data Update from its RP1 (vusolimogene oderparepvec) and RP2 Programs and Announces Plans to Expand the Development of RP2/3 Beyond Phase 1 High rate of complete responses in RP1 skin cancer cohorts underscore the potential for profound patient benefit and

May 20, 2021

Replimune Reports Fiscal Fourth Quarter and Year-Ended 2021 Financial Results and Provides Corporate Update Added complete response as an independent primary endpoint in registration-directed CERPASS study in CSCC and he

Replimune Reports Fiscal Fourth Quarter and Year-Ended 2021 Financial Results and Provides Corporate Update Added complete response as an independent primary endpoint in registration-directed CERPASS study in CSCC and held Type B meeting with FDA to discuss the IGNYTE study in

May 10, 2021

Replimune Appoints Tanya Lewis as Chief Development Operations Officer Woburn, MA

Replimune Appoints Tanya Lewis as Chief Development Woburn, MA, May 10, 2021- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, today announced the strengthening of its executive team w

May 5, 2021

Replimune Provides a Regulatory Update for its Registration- Directed Clinical Trials Evaluating RP1 in Combination with Libtayo (cemiplimab) for the Treatment of CSCC & Evaluating RP1 in Combination with Opdivo (nivolum

Provides a Regulatory Update for its Registration- Directed Clinical Trials Evaluating RP1 in Combination with Libtayo (cemiplimab) for the Treatment of CSCC & Evaluating RP1 in Combination with Opdivo (nivolumab) in anti-PD1 Failed Woburn, MA, May 5, 2021 - Replimune Group, In

Apr 12, 2021

Replimune to Present New Biomarker & Pre-clinical Data for Lead Oncolytic Immunotherapy Programs at the 2021 American Association for Cancer Research Annual Meeting Data confirms potent anti-tumor activity & activation o

Replimune to Present New Biomarker & Pre-clinical Data for Lead Oncolytic Immunotherapy Programs at the 2021 American Association for Cancer Research Data confirms potent anti-tumor activity & activation of robust systemic immune responses by RP1 and RP2 Woburn, MA, April 12,

Feb 4, 2021

Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update RP1: Initial data in new indications expected in 2021 in anti-PD1 failed NSCLC, anti-PD1 failed CSCC and CSCC solid organ transplant

Reports Third Fiscal Quarter Financial Results and Provides Initial data in new indications expected in 2021 in anti-PD1 failed NSCLC, anti-PD1 failed CSCC and CSCC solid organ transplant recipient patients; further updates expected to be provided across all studies data to be

Jan 11, 2021

Replimune Provides 2020 Year End Review and Overview of Expected 2021 Milestones RP1; Data in new indications expected in 2021 in anti-PD1 failed NSCLC, anti-PD1 failed CSCC and CSCC solid organ transplant recipient pati

Provides 2020 Year End Review and Overview of Expected 2021 Milestones Data in new indications expected in 2021 in anti-PD1 failed NSCLC, anti-PD1 failed CSCC and CSCC solid organ transplant recipient patients; further updates expected to be provided across all studies RP2; Ne

Nov 5, 2020

Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update RP1: Updated deep and durable response data with Opdivo in CSCC and anti-PD1 failed melanoma continue to support ongoing registratio

Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update RP1: Updated deep and durable response data with Opdivo in CSCC and anti-PD1 failed melanoma continue to support ongoing registration-directed development RP2: Single agent deep and durabl

Oct 19, 2020

Replimune Appoints Tanya Lewis to the Board of Directors Woburn, MA

Replimune Appoints Tanya Lewis to the Woburn, MA, October 19, 2020 - Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, today announced the appointment of Tanya Lewis to its Board of Dir

Oct 14, 2020

Replimune Announces Presentation at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Replimune Announces Presentation at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting Initial safety and efficacy data from the single agent RP2 portion of the Phase 1 clinical trial of RP2 alone & in combination with Opdivo ( nivolumab) in patients with solid

Sep 30, 2020

NEXT GENERATION ONCOLYTIC IMMUNOTHERAPY NEXT-GENERATION ONCOLYTIC IMMUNOTHERAPY Safe harbor 2 Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements wit

Cancer Res 24 2018 4 Ribas et al Lancet Oncology 19 2018; Hodi et al JCO 34 2016 5 Pires de Sliva et al ASCO 2020 RP1 in anti-PD1 failed melanoma data 15 October 15th 2020 status of the anti-PD1 failed cutaneous melanoma (N=16) patients dosed 87.5% stage IVM1b/ M1c ; very advance

Aug 7, 2020

Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update Clinical proof of principle established with RP1 in combination with Opdivo for the treatment of immune-responsive tumors supporting

Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update Clinical proof of principle established with RP1 in combination with Opdivo for the treatment of immune-responsive tumors supporting registration directed development in CSCC and anti-PD1 r

Jun 3, 2020

Replimune Reports Fiscal Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update Woburn, MA

Reports Fiscal Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update Woburn, MA, June 3, 2020 - Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing a series of oncolytic immuno-gene therapies derived from its Immulytic platform,

Jun 3, 2020

NEXT GENERATION ONCOLYTIC IMMUNOTHERAPY NEXT-GENERATION ONCOLYTIC IMMUNOTHERAPY Data Update June 3rd 2020 Safe harbor 2 Any statements contained herein that are not statements of historical facts may be deemed to be forw

Treated with RP1 combined with Opdivo Ongoing PR at 10 months BaselineC5C11BaselineC11 Esophageal cancer: CD8 T cell & PD-L1 staining 61 CD8PD-L1 Baseline Day 43 biopsy New cohort in anti-PD1 refractory NSCLC & termination of bladder cohort 62 Due to the changing competitive land

Apr 2, 2020

Replimune Appoints Dieter Weinand as Chairman and Paolo Pucci to the Board of Directors Woburn, MA

Replimune Appoints Dieter Weinand as Chairman and Paolo Pucci to the Board of Directors Woburn, MA, April 2, 2020 - Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, today announced the

Jan 13, 2020

Replimune Provides 2019 Year End Corporate Update and Reviews Expected 2020 Milestones

Replimune Provides 2019 Year End Corporate Update and Reviews Expected 2020 Milestones Registration-directed randomized controlled Phase 2 clinical trial of RP1 in combination with cemiplimab-rwlc (Libtayo ) in cutaneous squamous cell carcinoma (CSCC) underway RP1: Study of R

Jan 9, 2020

Replimune Announces the Evolution of its Management Team as it Advances Through Later Stage Clinical Development and Prepares for Commercialization Woburn, MA

the Evolution of its Management Team as it Advances Through Later Stage Clinical Development and Prepares for Commercialization Woburn, MA, January 9, 2020 - Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its

Nov 11, 2019

Replimune Reports Second Fiscal Quarter Financial Results and Provides Corporate Update RP1: Clinical data presented at the 34 th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2019) confirmed expected s

Replimune Reports Second Fiscal Quarter Financial Results and Provides Corporate Update RP1: Clinical data presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2019) confirmed expected safety profile and mechanism of action: Efficacy data support

Nov 8, 2019

NNEXEXT-TGGENENERERAATITOIONNOONNCCOOLYLYTITCIC IMIMMMUUNNOOTHTHERERAAPPYY SITC Investor Event Presentation November 8th 2019 Safe harbor 2 Any statements contained herein that are not statements of historical facts may

NNEXEXT-TGGENENERERAATITOIONNOONNCCOOLYLYTITCIC IMIMMMUUNNOOTHTHERERAAPPYY SITC Investor Event Presentation November 8th 2019 Safe harbor 2 Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements within the meani

Oct 15, 2019

Replimune Provides Update on RP1 Clinical Development Program in Cutaneous Squamous Cell Carcinoma First patient enrolled in registration-directed Phase 2 clinical trial of RP1 in combination with Regeneron and Sanofi s

Replimune Provides Update on RP1 Clinical Development Program in Cutaneous Squamous Cell Carcinoma First patient enrolled in registration-directed Phase 2 clinical trial of RP1 in combination with Regeneron and Sanofi s Libtayo in CSCC New clinical trial planned of RP1 as monot

Aug 14, 2019

Replimune Reports First Fiscal Quarter Financial Results and Provides Corporate Update RP1: Initial data from Phase 1 part of Phase 1/2 clinical trial alone and in combination with nivolumab expected to be presented in t

Replimune Reports First Fiscal Quarter Financial Results and Provides Corporate Update RP1: Initial data from Phase 1 part of Phase 1/2 clinical trial alone and in combination with nivolumab expected to be presented in the fourth calendar quarter of 2019 RP1: Enrollment is ongo

Jun 28, 2019

Replimune Reports Fourth Fiscal Quarter and Year 2019 Financial Results and Provides Corporate Update RP1: Initiated Phase 2 part of Phase 1/2 clinical trial of RP1 in combination with nivolumab in the U.S. and the U.K.

Replimune Reports Fourth Fiscal Quarter and Year 2019 Financial Results and Provides Corporate Update RP1: Initiated Phase 2 part of Phase 1/2 clinical trial of RP1 in combination with nivolumab in the U.S. and the U.K. RP1: Initial Data from Phase 1 part of Phase 1/2 clinical

Feb 14, 2019

Replimune Reports Financial Results for the Third Fiscal Quarter, Ended December 31, and Provides Development and Corporate Update RP1: Completed Single Agent Enrollment in Part 1 Portion of Phase 1/2 Clinical Trial in t

Replimune Reports Financial Results for the Third Fiscal Quarter, Ended December 31, and Provides Development and Corporate Update RP1: Completed Single Agent Enrollment in Part 1 Portion of Phase 1/2 Clinical Trial in the UK; Part 1 Enrollment Opened for Combination with Nivolu

Nov 14, 2018

Replimune Reports Financial Results for the Second Fiscal Quarter, Ended September 30, and Provides Development and Corporate Update U.S. Clinical Sites for Phase 1/2 Trial of RP1 in Patients with Solid Tumors on Track t

Replimune Reports Financial Results for the Second Fiscal Quarter, Ended September 30, and Provides Development and Corporate Update U.S. Clinical Sites for Phase 1/2 Trial of RP1 in Patients with Solid Tumors on Track to Initiate by End of Year Additional Product Candidates RP

Aug 30, 2018